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Abstract

Purpose
ONC201 is a small molecule selective antagonist of the G protein-coupled receptor DRD2 that
is the founding member of the imipridone class of compounds. A first-in-human phase I study
of ONC201 was conducted to determine its recommended phase II dose (RP2D).

Experimental Design
This open-label study treated 10 patients during dose escalation with histologically-confirmed
advanced solid tumors. Patients received ONC201 orally once every 3 weeks, defined as one
cycle, at doses from 125 to 625 mg using an accelerated titration design. An additional 18
patients were treated at the RP2D in an expansion phase to collect additional safety,
pharmacokinetic (PK), and pharmacodynamic (PD) information.

Results
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No Grade >1 drug-related adverse events occurred and the RP2D was defined as 625 mg. PK
analysis revealed a Cmax of 1.5 - 7.5 μg/mL (~3.9-19.4 μM), mean half-life of 11.3 hours, and
mean AUC of 37.7 h.ug/L. Pharmacodynamic assays demonstrated induction of caspasecleaved keratin 18 and prolactin as serum biomarkers of apoptosis and DRD2 antagonism,
respectively. No objective responses by RECIST were achieved, however, radiographic
regression of several individual metastatic lesions was observed along with prolonged stable
disease (> 9 cycles) in prostate and endometrial cancer patients.

Conclusion
ONC201 is a selective DRD2 antagonist that is well tolerated, achieves micromolar plasma
concentrations, and is biologically active in advanced cancer patients when orally administered
at 625 mg every 3 weeks.

Translational Relevance
There is a need for safe and effective therapies that meet the challenges of treating patients
with advanced cancers. ONC201 is an orally active small molecule that selectively antagonizes
the G protein-coupled receptor (GPCR) DRD2. Downstream of target engagement, the
mechanism of action of ONC201 involves the integrated stress response and inactivation of
Akt/ERK signaling, leading to upregulation of the pro-apoptotic immune cytokine TRAIL.
Preclinical studies have determined that ONC201 has prolonged anti-proliferative and proapoptotic effects against a broad range of tumor cells but not normal cells. The first-in-human
clinical trial of ONC201 in advanced solid tumors confirmed that ONC201 is exceptionally welltolerated at the recommended phase II dose of 625 mg every three weeks that exceeds
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targeted thresholds for dose, pharmacokinetics, and pharmacodynamics. Early signs of clinical
benefit were observed in advanced prostate and endometrial cancer patients.
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INTRODUCTION
ONC201 is a selective antagonist of DRD2 that causes downstream activation of the
integrated stress response (ISR) in tumor cells and is the founding member of the imipridone
class of compounds that share a unique chemical core structure [1, 2]. ONC201-induced
activation of the ISR via PERK-independent mechanism causes an early-stage increase in the
phosphorylation of eIF2-alpha at serine 51 that attenuates global translation and up-regulates
translation of the transcription factor ATF4. In turn, ATF4 induces CHOP, which is also a
transcription factor that regulates several apoptosis-related genes such as the TRAIL-receptor
DR5. Downstream anticancer signaling effects of ONC201 also include inactivation of the Ras
effector kinases – Akt and ERK – that upregulates TRAIL gene transcription via Foxo3a to
activate apoptosis in tumor cells. The ability of ONC201 to cause p53-independent induction of
the immune cytokine TRAIL and apoptosis in tumor cells underpinned its initial discover as an
anti-cancer compound [3]. ONC201 has exhibited pro-apoptotic anti-tumor effects, manifesting
as tumor regressions or stasis, as a single agent with infrequent oral dosing in numerous
subcutaneous and orthotopic advanced solid tumor models [3-6].

The safety profile of ONC201 in rat and dog toxicology studies was consistent with the
preferential cytotoxicity of ONC201 in tumor over normal cells in vitro [7]. An administration
schedule of once every 21 days was selected for clinical evaluation based on preclinical
results that indicate sustained intratumoral PD and that infrequent dosing was sufficient for in
vivo efficacy that did not significantly increase with more frequent administration. The antitumor
activity of ONC201 has been shown to be saturated at a dose of 25 mg/kg in murine models,
which is the human equivalent of approximately 125 mg.
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Based on the favorable efficacy and safety profile of ONC201, as well as its novel mechanism
of action, the clinical introduction of ONC201 in patients with advanced cancers was
undertaken [8]. The primary objective of this first-in-human, phase I dose-escalation study was
to determine the recommended phase II dose (RP2D) of ONC201 administered orally in
patients with advanced cancers, as well as to evaluate the safety and tolerability of the drug.
Secondary objectives included assessments of pharmacokinetics, pharmacodynamics and
preliminary anti-tumor activity of ONC201. Dose escalation was designed to proceed from a
starting dose of 125mg that is allometrically equivalent to the no-observed-adverse-event-level
(NOAEL) in Sprague Dawley rats and beagle dogs, up to a maximum administered dose of
625mg that is 5-fold above the expected therapeutic dose [7].

PATIENTS AND METHODS
Ethics
The study was carried at the Robert Wood Johnson University Hospital / Rutgers Cancer
Institute of New Jersey (CINJ) in accordance with the Declaration of Helsinki and the
International Conference on Harmonization Good Clinical Practice Guidelines and was
approved by relevant regulatory committees and the Institutional Review Board of CINJ.
Patients provided written, informed consent for their study participation.

Patient Population
Patients of 18 years of age or older with advanced solid tumors who refused or were
resistant to standard treatments, ECOG performance status of 0 or 1, and assessable
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disease by RECIST version 1.1 were eligible. Patients had to have finished all prior
cytotoxic chemotherapy at least 4 weeks, alkylating agents at least 6 weeks, molecularly
targeted agents at least 28 days, and radiotherapy at least 14 days prior to the first dose.
All prior treatment-related adverse events Grade > 2 except alopecia and neuropathy had
to have been resolved. Patients had to have exhibited normal marrow and organ function
as defined by the following parameters: absolute neutrophil count ≥ 1,500/mcL; platelets ≥
100,000/mcL; hemoglobin ≥ 9.0 mg/dL without transfusion in 2 prior weeks; total bilirubin
within normal range (for patients with liver metastases, serum bilirubin ≤ 1.5 x ULN); AST
(SGOT)/ALT (SGPT) ≤ 2.5 × upper limit of normal; and measured or estimated creatinine
clearance ≥ 40 mL/min/1.73 m2 for patients with creatinine levels above normal. Exclusion
criteria included symptomatic brain metastases or asymptomatic brain metastases treated
with steroids, prior bevacizumab treatment, prior allergic reactions to compounds similar to
ONC201, uncontrolled intercurrent illnesses, combination retroviral therapy for HIV, active
cardiac disease/history of cardiac dysfunction, stroke or seizures in the last 3 months,
impairment of GI function that may alter absorption of ONC201, pregnancy or treatment
with hematopoietic colony-stimulating growth factor ≤ 2 weeks prior to beginning treatment.

Study Design and Toxicity Assessment
The design was an open-label, dose-escalation phase I trial of monoagent ONC201 in
patients with advanced, refractory solid tumors who had exhausted or refused standard
treatment options for their respective indications. Capsules (125 mg) of ONC201 were
provided by Oncoceutics, Inc (Philadelphia, PA) containing the dihydrochloride salt form of
the compound. ONC201 was administered orally once every 21-day cycle without food
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intake two hours before or after drug administration. In the absence of dose-limiting toxicity,
dose escalation was designed proceed to a maximum administered dose of 625mg that is
5-fold higher than the therapeutic dose in preclinical models, using the following dose
increments: 125, 250, 375, 500, and 625mg. The primary objective of the study was to
determine the recommended Phase II (RP2D) of ONC201 administered every three weeks
that was defined was the maximum tolerated dose (MTD) or, in the absence of MTD, the
maximum administered dose. The study was conducted with a single patient accelerated
dose escalation design [9] that would cease if any patient experienced a Grade > I adverse
event that was attributed as at least possibly-related to ONC201. In this case a traditional
3+3 dose escalation design would have been employed. With either dose escalation
design, the RP2D was to be established in 6 patients in the appropriate dose cohort. Dose
escalation could proceed after the previously dosed cohort completed one treatment cycle
and met the criteria to proceed with the next dose level. Enrollment at each subsequent
dose level required that all patients enrolled at the prior dose level completed Cycle 1
dosing and were evaluated 21 days later to assess safety. Dose levels proceeded from 125
mg to 250 mg, 375 mg, 500 mg and finally to 625 mg. Following determination of the
RP2D, an expansion phase of 18 patients at the RP2D was completed to increase the
robustness of the safety profile.

All toxicities were evaluated based on the Common Terminology Criteria for Adverse Events
version 4. DLT was defined as a drug-related adverse event or abnormal laboratory result that
occurred in the first cycle of treatment that met any of the following criteria: ≥ Grade 3 nonhematological toxicity; ≥ Grade 3 nausea, vomiting, or diarrhea that has persisted for > 72
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hours despite optimal antiemetic or antidiarrheal therapy; Grade 3-4 AST/ALT in combination
with a Grade 2 elevation in bilirubin; Grade 4 neutropenia lasting = 7 days; Grade 4
neutropenia and fever of > 38.5°C; Grade 3 neutropenia with > Grade 3 infection;
thrombocytopenia of any grade if associated with clinically significant bleeding; Grade 4
thrombocytopenia; or Grade 4 anemia and was assessed as unrelated to disease, disease
progression, inter-current illness, or concomitant medications; and is determined by the
investigator to be “possibly related”, “probably related” or “definitely related” to the
administration of ONC201.

Safety Assessments
Safety assessments including complete blood count, serum chemistry, and toxicity were
evaluated at baseline, followed by weekly during the first 2 cycles, and then every 3 weeks
afterward.

Electrocardiograph

monitoring

was

carried

out

just

before

ONC201

administration, followed by 15 minutes, 1 hour and 2 hours, after drug administration.
Adverse events were graded using the CTCAE version 4.0. Disease assessments were
performed using RECIST version 1.1 every 2 cycles except for prostate cancer patients,
which were performed using the Prostate Cancer Clinical Trials Working Group (PCWG2)
criteria in lieu of RECIST.

Pharmacokinetic Analyses
Plasma samples for PK were collected at baseline, 30 minutes, 2 hours, 4 hours, 6 hours,
24 hours, 48 hours, and 168 hours following the first dose of ONC201 and before doses
prior to treatment in cycles 2-6. PK was analyzed using 50 uL of K2EDTA plasma by a
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validated LC-MS/MS method with positive ESI-MRM mode that has a linear range of 1 to
500 ng/mL (samples were diluted if above limit of detection). Deuterated ONC201 was
used as an internal standard.

Statistical Analysis
Descriptive statistics were used for the analysis of safety and tumor response data. Noncompartmental PK analysis was performed using Phoenix® WinNonlin® Version 6.3
(Pharsight®, St. Louis, Missouri).

Pharmacodynamic Analyses
ONC201 induces apoptosis in epithelial tumor cells in preclinical models, which can be
measured by caspase-cleaved cytokeratin 18 (cCK18) [10]. Antagonism of DRD2, which is
a direct effect of ONC201 [11], has been shown to induce the neuroendocrine hormone
prolactin that is secreted into the blood [12]. Thus, cCK18 and prolactin were selected as
serum PD biomarkers to be assessed in this heterogeneous patient population.

Blood samples for PD were collected at 6 hours, days 2, 3, 8, and 15 after ONC201
treatment for cycle 1, and pre-dose on the day of drug administration for cycle 2 and 3.
Serum levels of cCK18 were assessed using the M30 assay, serum levels of total
cytokeratin 18 (CK18) were assessed using the M65 assay (Perviva A.B., Sweden), and
serum levels of prolactin were assessed by ELISA (Human Prolactin Quantikine ELISA kit,
R&D Systems, Minneapolis, Minnesota) according to the manufacturer’s instructions.
Assessments of other tumor-specific markers were also evaluated per standard of care.
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RESULTS
Demographics, Safety, and Determination of RP2D
Ten heavily pretreated patients with diverse advanced solid tumors were enrolled in the dose
escalation phase of this study between January and July 2015 (Table 1; Supplemental Table
1). Dose cohorts ranged from the starting dose of 125 mg up to 625 mg, which was designed
as the maximum administered dose that exceeds the expected therapeutic dose by 5-fold and
was determined to be the RP2D. The only adverse event during the dose escalation phase
that was attributed as possibly-related to ONC201 was a Grade 1 fever in one patient treated
at a dose of 125mg (Table 2; Supplemental Table 2).

Following completion of the dose escalation phase, an additional 18 advanced cancer patients
were enrolled in an expansion phase between August 2015 and February 2016 with an
enrichment of prostate and endometrial cancer patients based on observations in dose
escalation. The only adverse events among these 18 patients that were attributed as possiblyrelated to ONC201 were nausea in one patient, emesis in one patient, and increased serum
amylase in two patients. All of these adverse events were Grade 1 and reversed rapidly.

Pharmacokinetics
Plasma collected at serial time points during the first cycle was used to analyze systemic
exposure to ONC201 and determine pharmacokinetic parameters (Figure 1; Supplemental
Figure 1; Supplemental Tables 3-4). Trends of increasing exposure with dose were consistent
with dose proportionality. Patients receiving 625mg ONC201 exhibited a mean half-life of 11.3
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hours and achieved a mean Cmax of 3.6 ug/mL (~9.3 uM), which occurred at 1.8 hours
following administration (Tmax) and surpassed the target Cmax of 1 ug/mL. The mean volume
of distribution was 369 L, consistent with a large distributive volume and penetrance of target
tissues observed in animals.

Mean AUC was 37.7 h.μg/mL and mean CL/F was 25.2 L/h, which was generally observed to
be variable but consistent across all dose groups (Supplemental Figure 2A). There were no
apparent relationships between drug CL/F and patient sex and age (Supplemental Figure 2BC). Noticeable, shallow trends were observed with patient weight and BSA (Supplemental
Figure 2D-E). An overall increase in CL/F was observed as weight and BSA increased.
Although a slight upward trend was observed, there was no strong correlation between CL/F
and CLCR (Supplemental Figure 2F).

Stronger correlations were observed with the distributive volume estimate and patient weight
and BSA. An increase in volume of distribution was observed with increasing patient weight or
BSA, as expected (Supplemental Figure 2G-H). Trends of decreasing exposure with
increasing weight were observed in plots of Cmax/Dose and AUC/Dose versus patient weight
(Supplemental Figure 2 I&J). Weight normalized CL/F was plotted versus Dose (Supplemental
Figure 2K), showing a similar trend to un-normalized CL/F.

Pharmacodynamics
As a biomarker of apoptosis, the serum M30 and M65 assays were used to quantify serum
caspase-cleaved and total cytokeratin-18 [12-17]. As expected, the patient who remained on
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study through 9 cycles exhibited increases in the M30 assay, but not in the M65 assay
(Supplemental Figure 3). In contrast, the patient with rapid disease progression who was on
study for less than one cycle exhibited increases in the M65, but not in the M30 assay. Four of
the patients enrolled in the dose escalation phase of the study had an induction in the M30
assay after a single dose of ONC201, most often on day 21 post-treatment (Figure 2A;
Supplemental Table 5). Given the downstream induction of TRAIL by ONC201 in preclinical
models, serum TRAIL levels were also quantified (Supplemental Figure 4). Half of the patients
exhibited a modest (~20%) increase in serum TRAIL that mostly peaked within the first 24
hours of drug administration.

Serum prolactin, which is induced by DRD2 antagonism in the pituitary gland, was evaluated
as a surrogate marker of target engagement [12]. Twenty-two of the 25 patients evaluated in
this analysis exhibited induction of prolactin over baseline. The mean peak induction of
prolactin was 2.4-fold over baseline (P=0.000034) (Figure 2B and Supplemental Figure 5).
Interestingly, the patient exhibiting the strongest level of prolactin induction was the
endometrial cancer patient who had the reduction in lymphadenopathy. Prolactin induction
appeared to be more pronounced in patients with lower baseline levels. Peak induction tended
to occur at either the earliest evaluated time point, 6 hours post-dose, or much later at 14 or 21
days post-dose. Induction of prolactin did not correlate with ONC201 dose or PK parameters
(Supplemental Figure 6), suggesting that DRD2 antagonism occurs at the clinical evaluated
doses of ONC201 and in agreement with the dose escalation design that did not continue
above 625mg.
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Patient Outcomes
The overall mean number of ONC201 doses received was 3.3. Out of 28 evaluable patients,
10 patients completed at least 4 cycles, and 2 patients received at least 9 cycles
(Supplemental Table 5).

After 2 doses of 375mg ON201, one 72-year-old patient with

advanced clear cell endometrial cancer had a mixed response with multiple nodes decreasing
by >30% along with the development of new nodes. One 69-year-old patient with prostate
adenocarcinoma experienced prolonged stable disease and was on study for 27 weeks.

Based on these clinical observations in the dose escalation phase, the expansion phase
enriched for endometrial and prostate cancer patients. A 90-year old prostate cancer patient
underwent a rapid shrinking of his primary tumor and metastatic bone lesion (~25%) after only
two doses of 625mg ONC201. Waterfall analysis of the 28 patients on a lesion-by-lesion basis
revealed tumor regressions in prostate and endometrial cancer patients that involved lymph
nodes, bone, and lung lesions (Figure 3A). One endometrial cancer patient experienced stable
disease for 42 weeks and exhibited sustained regression of her metastatic lung lesion (Figure
3B).

DISCUSSION
This is the first human study of the selective DRD2 antagonist, ONC201. The primary objective
of the study was to determine the RP2D of oral ONC201 administered every 3 weeks to
patients with solid tumors who have exhausted all treatment options. As anticipated by the
preclinical safety profile of ONC201, no drug-related Grade >1 adverse events were observed
in any patients despite exposure to micromolar therapeutic plasma concentrations. The safety
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profile of the drug allowed the study to progress rapidly without digressing from the accelerated
titration design. To address the small sample size in the dose escalation phase, the safety
profile of RP2D was confirmed in the 18-patient expansion phase.

The pharmacokinetic profile of ONC201 at the RP2D indicates significant absorption of the
drug with oral administration that was rapid, as indicated by the 1.8 hour mean Tmax.
Importantly, the PK parameters such as Cmax and AUC in the top dose cohort treated at the
RP2D exceeded those associated with the antitumor efficacy in mouse models and the
NOAEL in toxicology studies. While serum prolactin is a surrogate marker within inherent
limitations, the results in this study indicate that ONC201 engages its target in advanced
cancer patients at, and below, its recommended phase 2 dose of 625mg. Like preclinical
findings, PD measurements of apoptosis with the M30 assay revealed that the effects of
ONC201 were sustained over time in several patients. Serum TRAIL induction was noted in 2
patients; however, this assay is limited to the detection of serum soluble TRAIL as ontreatment tumor biopsies were not available for evaluation.

This study selected the target dose of 625 mg administered once every 3 weeks as the RP2D,
which is 5-fold above the expected therapeutic dose based on preclinical models and
allometric conversion. In support of this dose selection, the PK parameters exceeded
thresholds derived from preclinical models and the observed PD supports target engagement
at and below the RP2D. Given that the primary endpoint of the study was based on clinical
safety in a group of heterogeneous and heavily-pretreated patients with aggressive cancers, it
is noteworthy that some patients showed some evidence of clinical benefit. These included a
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patient with chemo-resistant clear cell endometrial cancer who had a mixed response, 2
patients who had alleviation of symptoms associated with sites of tumor manifestation, and 2
patients (castrate-resistant prostate and Type 2 endometrial cancers) with stable disease for >
9 cycles. Even though objective responses were not achieved by RECIST criteria, there were
several instances of regressions in individual lesions of prostate and endometrial cancer
patients.

Given the benign safety profile of the drug established in this trial, other clinical studies are
exploring more frequent ONC201 dose regimens. The signs of anti-tumor activity and absence
of any meaningful side effects in this trial indicate that ONC201 may offer clinical benefit
without imposing the typical toxicities of anticancer therapies. Several ongoing clinical trials are
investigating the activity of ONC201 in advanced cancers that exhibit preclinical sensitivity to
the

compound

and

where

the

mechanism

of

action

is

relevant:

glioblastoma,

pheochromocytoma, endometrial cancer, non-Hodgkin’s lymphoma, multiple myeloma, and
acute myeloid leukemia.

In conclusion, this study demonstrates that ONC201 is very well tolerated at the RP2D of
625mg, achieves its anticipated PK profile, and exhibits signs of activity in patients with
advanced solid tumors that warrants further investigation in several ongoing advanced cancer
clinical trials [8].

Acknowledgements: The authors thank Lee Schalop, MD for his careful review of the
manuscript and his constructive suggestions.
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Figures
Figure 1: ONC201 plasma concentrations following the first dose of ONC201.
Concentrations are shown as (A) the mean for each dose cohort in dose escalation, or (B) for
all individuals treated at 625 mg. Data points below the limit of detection (1ng/mL) are
excluded from the plots. Error bars indicate standard deviation.

Figure 2: Pharmacodynamic assays for apoptosis and DRD2 antagonism. (A) M30 assay
ratio in dose escalation patients who experienced induction over baseline (n=2 per sample).
(B) Maximum versus baseline serum prolactin levels in dose-escalation cohort of patients.

Figure 3: Antitumor activity in metastatic lesions. (A) Waterfall analysis on a lesion-bylesion basis. Best change in lesion size is defined as the maximal reduction or minimal
increase in sum of longest dimensions of target lesions relative to pretreatment assessment.
25/28 patients had measurable tumors at baseline and at least one post-treatment evaluation.
Letters above or below bar denotes location of the lesion: V = liver; L = lung; N = lymph node;
A = adrenal gland; P = primary tumor; B = bone. (B) Metastatic lung lesion of an endometrial
cancer patient at baseline and after 8 doses of 625mg ONC201.
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Tables
Table 1: Patient demographics. * indicate the mean with the range in parentheses.
Dose escalation cohorts
(n=10)

Dose expansion
(n=18)

Male

5

8

Female

5

10

Age (years)*

66.8 (47-80)

60.1 (26-90)

Weight (kg)*

76 (47.7-123)

73 (47.7-118.9)

Cycles/Doses of ONC201*

3.2 (1-4)

3.3 (1-14)

Prior therapies*

5.5 (1-10)

6.2 (3-18)

Prior radiation

5

12

Prior surgeries

9

13

Table 2. Adverse events. All adverse events attributed as at least possibly-related to ONC201
were Grade 1 (n=28).
ONC201 (mg)
No of Patients
Pyrexia
Fatigue
Elevated amylase
Emesis
Nausea

125
1
1 (3.6%)
1 (3.6%)
0
0
0

250
1
0
0
0
0
0

375
1
0
0
0
0
0

500
1
0
0
0
0
0

625
24
0
0
2 (7.2%)
1 (3.6%)
1 (3.6%)
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Table 3. Pharmacokinetic parameters for 625 mg ONC201 (N=24).

Cmax

Tmax

Tlag

AUClast

λZ

t1/2

AUC

VZ/F

CL/F

(ug/mL)

(h)

(h)

(h.ug/mL)

(h-1)

(h)

(h.ng/mL)

(L)

(L/h)

Mean

3.6

1.8

0.02

37.0

0.076

11.3

37.7

369

25.19

SD

2.6

0.9

0.08

41.6

0.046

5.2

41.6

193

14.22
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